• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vaxcyte Inc (NQ: PCVX )

    80.06 +0.72 (+0.90%)
    Streaming Delayed Price Updated: 10:37 AM EDT, Jul 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 147,577
    Open 79.32
    Bid (Size) 79.97 (1)
    Ask (Size) 80.21 (4)
    Prev. Close 79.35
    Today's Range 79.17 - 80.61
    52wk Range 44.20 - 82.04
    Shares Outstanding 93,706,790
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Vaxcyte Appoints John Furey to Board of Directors
    From Vaxcyte, Inc.
    Via GlobeNewswire
    PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
    PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +27.21%
    +27.21%
    1 Month
    +11.39%
    +11.39%
    3 Month
    +24.93%
    +24.93%
    6 Month
    +31.88%
    +31.88%
    1 Year
    +68.17%
    +68.17%

    More News

    Read More
    Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
    Via Benzinga
    Recap: Vaxcyte Q4 Earnings
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte Announces Pricing of $750 Million Public Offering
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte Appoints Whitney Jones as Chief People Officer
    From Vaxcyte, Inc.
    Via GlobeNewswire
    "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
    Via Benzinga
    Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst
    Via Benzinga
    VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte Appoints Jacks Lee to Board of Directors
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
    From Vaxcyte, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.